When you look at Stanley Druckenmiller's latest 13F, the headline names are familiar. He added Amazon and Alphabet again. That fits the narrative most people expect from a billionaire macro investor. What surprised me was that his single biggest holding was neither of those giants nor Nvidia. It was a genetic testing company called Natera (NTRA -2.03%).
That tells me something important. When a guy with Druckenmiller's track record makes a company almost one-fifth of his portfolio, I pay attention to what that business does and why it might be worth that kind of conviction. So instead of asking why he owns more Amazon, I find myself asking why he is willing to let a mid-cap diagnostics stock sit at the top of the stack.
NASDAQ: NTRA
Key Data Points
What is Natera?
Natera is not a household consumer brand. It is a molecular diagnostics company focused on cell-free DNA testing. In plain language, it analyzes tiny fragments of DNA circulating in blood to answer questions about pregnancy, cancer, and organ health.
Its three main franchises are women's health, oncology, and transplant surveillance. Panorama screens for genetic conditions in unborn babies, Horizon checks parents for carrier status, Signatera tracks cancer recurrence, and Prospera monitors transplant rejection.
Stanley Druckenmiller, Duquesne Family Office Chairman. Image source: Getty Images.
What customers actually buy is not a kit like the one you might get at a pharmacy. They buy a test result. A sample goes to Natera's labs, their algorithms and lab workflow process it, and a report goes back to the doctor. Revenue mostly comes from per-test reimbursement, paid by Medicare, private insurers, and health systems. Oncology and transplant programs also generate revenue through biopharma partnerships and companion diagnostics.
For Druckenmiller, this does not look like a sleepy lab business. Natera's growth is real. In Q1 2026, total revenue reached about $696.6 million, up nearly 39% year over year. Oncology volumes jumped 54%, and the company processed over one million tests in a single quarter for the first time in its history. In Q2 2026, revenue climbed again to $752.8 million with gross margin around 64.5%. Natera processed about 1,043,900 tests, including almost 297,000 oncology tests, and raised full-year guidance to a range of $2.85 billion to $2.91 billion in revenue. Management now expects cash flow to be positive for the year.
NASDAQ: GOOG
Key Data Points
Signatera is the X-factor
Under the hood, Signatera is the piece that keeps catching my eye. This is Natera's personalized molecular residual disease test, built to detect tiny traces of cancer DNA left after treatment or surgery. Natera has trained AI models on data from more than 300,000 patients tested with Signatera, integrating longitudinal blood results, digital pathology, and tumor sequencing.
That data helps refine risk scores and treatment decisions in ways standard imaging cannot. The company has secured the first FDA-approved companion diagnostic for blood-based MRD, the first PMDA-approved MRD test in Japan, and the first EU IVDR-certified personalized MRD test for solid tumors, along with a top-tier guideline recommendation for bladder cancer.
To me, that is the outline of a platform, not a single product. Every new cancer indication, every new guideline, and every new partnership adds another layer to a data asset that is hard to replicate. Of course, this is still biotech. Natera spends heavily on sales and research. For 2026, the company expects selling, general, and administrative expenses of around $1.1 billion to $1.2 billion and research and development expenses of around $800 million to $900 million. Regulatory risk, reimbursement changes, and competition all matter. The stock has already run a lot, which raises valuation questions.
That is why I do not read his Natera bet as a simple recommendation to pile in blindly. What I take from it is a view that the next decade of healthcare will include much more personalized, blood-based testing, and that owning a leader in cell-free DNA and MRD could be as important as owning a leader in AI chips. Druckenmiller can buy Amazon, Alphabet, and semiconductors like everyone else. The fact that he lets Natera sit at the top of his portfolio says he thinks this kind of diagnostics platform has a shot at becoming a core part of how medicine works.
